RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with aggressive blood cancers: experimental immune cell therapy trial opens
Disease control Recruiting nowThis study is testing an experimental treatment called Obe-cel for children and teenagers whose B-cell leukemia or lymphoma has returned or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and …
Matched conditions: RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough lymphomas: first patients test experimental drug
Disease control Recruiting nowThis is the first time a new drug called YK012 is being tested in people. The study aims to find a safe dose and see if it helps patients with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers will enroll about 48 adults to check …
Matched conditions: RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug cocktail aims to tame tough lymphomas
Disease control Recruiting nowThis early-stage study is testing a combination of three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody—for people with certain slow-growing B-cell lymphomas that have come back or stopped responding to prior treatments. The main goal is to find the safest and most e…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether an oral drug called pemigatinib can help control two specific types of B-cell non-Hodgkin lymphoma that have come back or stopped responding to standard treatments. It is for adults with mantle cell lymphoma or marginal zone lymphoma who have already…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
First-in-Human cancer drug trial seeks to tame tough lymphoma
Disease control Recruiting nowThis is the first study to test a new immunotherapy drug called MK-1045 in people. The goal is to find a safe dose and see if it can help patients with B-cell non-Hodgkin lymphoma that has come back or stopped responding to other treatments. Researchers will give the drug to abou…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated Mar 02, 2026 15:28 UTC